Immune thrombocytopenia: no longer 'idiopathic'
- PMID: 21632906
- PMCID: PMC3410635
- DOI: 10.3949/ccjm.78gr.10005
Immune thrombocytopenia: no longer 'idiopathic'
Abstract
Immune thrombocytopenia (ITP) is a common hematologic disorder. Its pathogenesis involves both accelerated platelet destruction and impaired platelet production. First-line agents are usually effective initially but do not provide long-term responses. Splenectomy remains an effective long-term therapy, as does rituximab (Rituxan) in a subset of patients. Thrombopoietic agents offer a new alternative, although their place in the overall management of ITP remains uncertain.
References
-
- Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–2393. - PubMed
-
- Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS, Logie J. The incidence of idiopathic thrombocytoenic purpura among adults: a population-based study and literature review. Eur Haematol. 2009;83:83–89. - PubMed
-
- Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR Northern Region Haematology Group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122:966– 974. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources